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ABSTRACT The type VII secretion systems are conserved across mycobacterial species and in many Gram-positive bacteria. While
the well-characterized Esx-1 pathway is required for the virulence of pathogenic mycobacteria and conjugation in the model or-
ganismMycobacterium smegmatis, Esx-3 contributes to mycobactin-mediated iron acquisition in these bacteria. Here we show
that several Esx-3 components are individually required for function under low-iron conditions but that at least one, the
membrane-bound protease MycP3 ofM. smegmatis, is partially expendable. All of the esx-3mutants tested, including the
mycP3msmutant, failed to export the native Esx-3 substrates EsxHms and EsxGms to quantifiable levels, as determined by tar-
geted mass spectrometry. Although we were able to restore low-iron growth to the esx-3mutants by genetic complementation,
we found a wide range of complementation levels for protein export. Indeed, minute quantities of extracellular EsxHms and
EsxGmswere sufficient for iron acquisition under our experimental conditions. The apparent separation of Esx-3 function in
iron acquisition from robust EsxGms and EsxHms secretion in themycP3msmutant and in some of the complemented esx-3mu-
tants compels reexamination of the structure-function relationships for type VII secretion systems.
IMPORTANCE Mycobacteria have several paralogous type VII secretion systems, Esx-1 through Esx-5. Whereas Esx-1 is required
for pathogenic mycobacteria to grow within an infected host, Esx-3 is essential for growth in vitro. We and others have shown
that Esx-3 is required for siderophore-mediated iron acquisition. In this work, we identify individual Esx-3 components that
contribute to this process. As in the Esx-1 system, most mutations that abolish Esx-3 protein export also disrupt its function.
Unexpectedly, however, ultrasensitive quantitation of Esx-3 secretion by multiple-reaction-monitoring mass spectrometry
(MRM-MS) revealed that very low levels of export were sufficient for iron acquisition under similar conditions. Although pro-
tein export clearly contributes to type VII function, the relationship is not absolute.
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One of the many strategies evolved by Mycobacterium tubercu-losis to prevent clearance by the host is protein export via
Esx-1 (1–3), a specialized secretion system that is also required for
conjugation in M. smegmatis (4, 5). There are four paralogous esx
loci in theM. tuberculosis genome (6–8), but the functions of these
Esx systems are just beginning to be revealed (9–19, 55).
Whereas Esx-1 is essential for the in vivo growth of pathogenic
mycobacteria, there is strong evidence that Esx-3 is essential for in
vitro growth (12, 13, 19, 20). Building on observations that esx-3
expression responds to iron and zinc availability (21, 22), we and
others have demonstrated that Esx-3 is required for mycobacterial
growth in low iron (12, 13, 19). Mycobacteria acquire iron by at
least two siderophore pathways— exochelin, present in fast-
growing species, such asM. smegmatis, and mycobactin, present in
nearly all species (23–25)—in addition to a porin-based, low-
affinity iron transport system (26) and the heme uptake system
(27, 28). Epistasis experiments using M. smegmatis strains with
deficiencies in Esx-3 and in the production of exochelin or myco-
bactin show that Esx-3 functions in iron acquisition via the my-
cobactin pathway (13). Moreover, addition of purified, iron-
bound mycobactin does not rescue the low-iron growth defect,
suggesting that Esx-3 is required for optimal utilization of the
siderophores (13).
The organizations and contents of the esx-1 and esx-3 loci are
similar (8). Both encode small, secreted proteins; Esx-1 contains
EsxB (Cfp-10) and EsxA (Esat-6), and Esx-3 contains the paralo-
gous EsxG and EsxH proteins (Fig. 1). We use the systematic no-
menclature proposed by Bitter et al. (29). Genes that flank esxB/A
and esxG/H include those encoding EccC3 (a putative FtsK/
SpoIIIE ATPase that is paralogous to EccCa1/EccCb1 [where the
“a” and “b” suffixes indicate the parts of the split gene and the
subscript number refers to the esx-1 gene cluster]), EspG3 (a pu-
tative soluble protein of unknown function that is paralogous to
EspG1), EccD3 (paralogous to the hypothesized secretion channel
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protein EccD1), and MycP3 (paralogous to the membrane-bound
protease MycP1) (8).
Multiple studies on the Esx-1 system support a model in which
the FtsK/SpoIIIE ATPase EccCa1/EccCb1 provides energy to pro-
pel EsxB and EsxA across the cytoplasmic membrane via a trans-
location pore composed of EccD1 (30–32). It is not yet clear how
type VII substrate proteins cross the cell envelope. Esx-1 may sim-
ply export these proteins across the cell envelope into the extra-
cellular space. Alternatively, it may act only across the cytoplasmic
membrane and require a mechanism for driving substrates across
the remainder of the thick mycobacterial cell wall. Such a structure
may be composed of yet-unidentified components or of EsxA,
EsxB, and possibly other unlinked Esx-1 substrates (33, 34).
EspG1, EccCa1/EccCb1, EccD1, and MycP1 are required for
both EsxB and EsxA export and Esx-1 function in most mycobac-
terial species tested (3, 5, 35–41), prompting early speculation that
EsxB and EsxA are the effector proteins of the secretion system.
However, there have since been reports of several Esx-1 mutations
that abolish function without affecting EsxB and EsxA export (4,
35, 42, 43), as well as two genetic perturbations that prevent M.
tuberculosis EsxB (EsxBmt) and EsxAmt secretion but do not alter
M. tuberculosis virulence (44). These studies suggest that the rela-
tionship between protein export and Esx function may be more
complicated than previously assumed.
Esx-3 exports EsxH (13) and, as we show here, EsxG. We found
that several M. smegmatis Esx-3 components were individually
required for export of EsxHms and EsxGms and for iron acquisi-
tion. However, we also observed low or even no detectable secre-
tion for some strains that were able to grow to wild-type levels in
low iron. The apparent separation of the phenotypes suggests new
models for the associations between Esx structure and function.
RESULTS
Esx-3 components are required for low-iron growth. We have
previously shown that Esx-3 is required for mycobacterial growth
in low-iron medium via the mycobactin pathway (13). The secre-
tion system is essential for growth in M. tuberculosis (12, 13, 20),
however, complicating efforts to test the contributions of individ-
ual Esx-3 components to the function of the entire system. The
model organism M. smegmatis can grow without functional Esx-3
in normal growth medium. We therefore constructed unmarked,
in-frame deletions of esx-3 genes in M. smegmatis (see Fig. S1 in
the supplemental material). Because M. smegmatis has partially
redundant siderophore-based iron acquisition mechanisms, i.e.,
FIG 1 Schematic diagram of gene conservation in mycobacterial esx-1 and esx-3 loci. , the M. smegmatis esx-1 locus has a slightly different organization than
the M. tuberculosis region from espJ to espB (5, 8); , there is no MSMEG_0625, mycP3ms is MSMEG_0624, and eccE3ms is MSMEG_0626. We use the
nomenclature proposed by Bitter et al. (29). Briefly, the terms ecc and esp, respectively, stand for esx conserved component and Esx-1 secretion-associated protein.
The alphabetic suffix of conserved esx genes follows the gene order in the esx-1 locus. The numerical subscript at the end of the gene name refers to the esx cluster
to which the gene belongs. We also provide the standard M. tuberculosis and M. smegmatis gene numbers at the beginning and end of each locus for comparison.
Although not listed in the NCBI or SmegmaList databases, MSMEG_0620 is esxGms and MSMEG_0621 is esxHms.
Siegrist et al.
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the mycobactin and exochelin pathways (24), we combined each
esx-3 deletion with an insertional mutation in fxbA, which en-
codes a formyl transferase required for exochelin synthesis. Previ-
ously, we found that the fxbAeccC3ms mutant grows significantly
more slowly than the fxbA strain in low-iron medium (13). Al-
though the fxbA esxGHms, fxbA espG3ms, and fxbA eccD3ms
mutants display similar low-iron growth deficiencies, the fxbA
mycP3ms strain has a less pronounced defect (Fig. 2 and 3). These
strains are rescued by the presence of iron (Fig. S2) and upon
reintroduction of the corresponding esx-3 gene (13) (Fig. 2).
Thus, M. smegmatis growth in low iron requires the Esx-3 com-
ponents EccC3ms, EsxGms/EsxHms, EspG3ms, and EccD3ms, with a
more minor contribution from MycP3ms.
Esx-3 components contribute tooptimalmycobactinutiliza-
tion. Previously, we constructed an M. smegmatis strain that con-
tains insertions in both fxbA, described above, and mbtD, which
encodes a polyketide synthase required for mycobactin synthesis
(13). This mutant, which lacks both means of high-affinity iron
uptake, does not grow in iron-depleted medium but can be res-
cued by the addition of purified, iron-bound mycobactin or car-
boxymycobactin (13). However, the siderophores fail to rescue
the fxbA esx-3 mutant, suggesting that Esx-3 is required for op-
timal utilization of iron bound to mycobactins (13). In the ab-
sence of the exochelin pathway, deletion of the esx-3 gene eccC3ms,
esxGHms, espG3ms, or eccD3ms impairs iron-bound mycobactin uti-
lization in M. smegmatis to an extent similar to that after removal
of the entire Esx-3 system, whereas deletion ofmycP3ms has a more
modest effect (Fig. 3). We conclude that the Esx-3 components
EccC3ms, EsxGms/EsxHms, EspG3ms, and EccD3ms are critical to the
function of the M. smegmatis Esx-3 system in mycobactin-
mediated iron acquisition.
Secretion of EsxHms and EsxGms requires Esx-3 components.
Secretion of EsxB and EsxA is generally linked to Esx-1 function;
that is, most mutations that abolish export of these proteins also
inhibit virulence (M. tuberculosis and M. marinum) or conjuga-
tion (M. smegmatis) (3–5, 35–40). Our work on the Esx-3 system
demonstrates that EccC3ms, EsxGms/EsxHms, EspG3ms, and
EccD3ms are required for function in mycobactin-mediated iron
acquisition and that MycP3ms plays a more limited role (Fig. 2 and
3). Previously, we showed that export of heterologously expressed,
myc-tagged EsxH depends on iron levels and on the presence of an
intact Esx-3 locus (13). To test whether the loss of individual Esx-3
FIG 2 Esx-3 components contribute to low-iron growth. The growth of the fxbA and fxbA esx-3 M. smegmatis mutants in low-iron medium was monitored by
determining their optical densities at 600 nm. pJ, pJEB402 vector; pJ-[gene name], pJEB402 containing the indicated M. smegmatis gene. The experiments were
performed 2 to 6 times in triplicate. Representative data are shown, and error bars represent the standard deviations from the replicates.
Esx-3 Components Contribute to Mycobacterial Iron Acquisition
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components similarly influences protein export, we monitored
the abundance of representative EsxGms and EsxHms peptides in
culture filtrates and selected whole-cell extracts by targeted, quan-
titative mass spectrometry (MS). Assays for peptides from each of
these proteins were constructed using stable-isotope dilution MS
(SID-MS) and multiple-reaction-monitoring MS (MRM-MS)
(45, 46). For these experiments, we grew strains with intact exo-
chelin production in medium with a level of iron chelation that
induces EsxH secretion (13) but does not produce differences in
growth. Deletion of the esx-3 gene eccC3ms, esxGHms, espG3ms, or
eccD3ms results in supernatant levels of EsxHms and EsxGms that are
below the limit of quantitation (LOQ) across two biological rep-
licates (Fig. 4 and S3 to S5 in the supplemental material). Interest-
ingly, although the mycP3ms mutation causes a much smaller de-
fect in low-iron growth than the other mutations (Fig. 2), there is
a comparable decrease in supernatant peptides in three of the four
data sets to levels below the LOQ (Fig. 4 and S3 to S5).
We find most of the detectable EsxHms and EsxGms in the su-
pernatant fraction of wild-type M. smegmatis (Fig. 4 and S5). To
test whether the observed lack of secretion by the esx-3 mutants
reflects a general decrease in protein expression, we also compared
the whole-cell extracts of the wild type, espG3ms mutant, and
complemented espG3ms strain. The amounts of EsxHms and
EsxGms were similar across the samples (Fig. S5), suggesting that
the observed change in supernatant abundance accurately reports
an export defect. The general lack of protein accumulation in the
whole-cell extract, furthermore, implies that the cell tightly regu-
lates the abundance of what we hypothesize is a small, cytoplasmic
pool of EsxHms and EsxGms.
These data were consistent with our previous findings that
Esx-3 is required for the export of EsxHms-myc (13). Unlike native
EsxGms and EsxHms, however, the tagged protein accumulates in
the bacterial cytoplasm to robust levels (13). Therefore, we con-
firmed the mass spectrometry findings by constructing a new plas-
mid that constitutively expresses esxGms and FLAG-tagged esxHms
and comparable amounts of EsxHms-FLAG in cell-associated and
supernatant fractions of wild-type and esx-3mutantM. smegmatis
strains. In agreement with the MRM-MS results, we were consis-
tently unable to detect EsxHms-FLAG from the supernatants of the
eccC3ms, espG3ms, eccD3ms, and mycP3ms mutants or from
any of the whole-cell extracts (Fig. 5).
DISCUSSION
We found that EccC3ms, EspG3ms, and EccD3ms are core Esx-3
components that are required for both mycobactin-mediated iron
acquisition and EsxGms and EsxHms export. The M. tuberculosis
homologs EccC3mt, EspG3mt, and EccD3mt are all predicted to be
necessary for in vitro growth (20, 47, 48). The Esx-1 paralogs
EccCa1/EccCb1, EspG1, and EccD1 are required for virulence in
pathogenic mycobacteria and conjugation in M. smegmatis and,
with the exception of EspG1mt (35, 42), for EsxB and EsxA export
(3–5, 35–40).
We have also identified a potential accessory Esx-3 compo-
nent, MycP3, that is necessary for EsxG and EsxH export (Fig. 4
and 5) but not absolutely required for mycobactin-mediated iron
acquisition (Fig. 2 and 3). The first observation is not unexpected,
as mutants that lack MycP1 fail to secrete EsxB and EsxA (36, 41).
The data on the contribution of MycP to Esx function are less
clear; although MycP1ms is required for DNA transfer in M. smeg-
matis to the same or greater extent as other Esx-1 components (4,
36),mycP1mt disruption inM. tuberculosis results in a delayed phe-
notype in mice compared to the phenotypes resulting from trans-
poson insertions in other esx-1 genes (49). More recent work cor-
roborates an in vivo growth defect from loss of MycP1mt (41), but
the lack of a direct comparison to other esx-1 mutant strains pre-
cluded analysis of the relative defect. Like the other esx-3 genes,
mycP3mt is essential for M. tuberculosis growth in vitro (47). Given
that MycP1 and MycP3 likely have different substrate specificities
FIG 3 Loss of Esx-3 components is not rescued by exogenous mycobactin. Growth of fxbA, fxbA mbtD, and fxbA esx-3 mutants in unsupplemented, low-iron
medium or in low-iron medium containing 20g/ml mycobactin S at 48 h. The experiment was performed at least three times in triplicate. Representative data
are shown and are expressed as percentages of the fxbA mutant’s growth in low-iron medium. Error bars indicate the standard errors of the proportions.
Siegrist et al.
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FIG 4 EsxGms (A) and EsxHms (B) abundances in wild-type and esx-3 mutant supernatants. Protein concentrations for EsxGms and EsxHms were approximated,
respectively, by measuring the concentration of the FVEVSAK peptide alone and by summing the individual concentrations above the LOD of three of the
methionine forms of AMATTHEQNTMAMSAR peptides (Fig. S4). Dotted lines show the LOQ (Fig. S4). The experiments were performed in technical replicate
across two biological replicates. The protein abundance data from one of the biological replicates are shown here in graphical and table format, and the data from
the other replicate are reported in the Fig. S5 table. comp, complemented; ND, none detected.
FIG 5 Export of epitope-tagged EsxHms in the presence or absence of Esx-3 components. Anti-FLAG immunoblotting of whole-cell lysates (wcl) and culture
supernatants (sup) from wild-type and esx-3M. smegmatis containing pSYMP-esxGHms-FLAG in low-iron medium. All strains contain either the empty pJEB402
vector or pJEB402 containing the complementing gene. The antibody against the intracellular protein RNAP is a loading and lysis control. The experiment was
performed twice with similar results.
Esx-3 Components Contribute to Mycobacterial Iron Acquisition
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(41, 50, 51), it may be that the relative importance of MycP as an
Esx component varies according to the secretion apparatus with
which it associates.
Despite our attempts to avoid polar effects by constructing
in-frame, unmarked, full gene deletions, it is possible that the
mutations altered the expression of downstream genes. However,
this does not appear to be the case for at least the mycP3ms mu-
tant, as neither mycP3ms alone nor mycP3ms alongside the down-
stream eccE3ms restored EsxHms-FLAG export (not shown). Tran-
scription of the esx-3 locus varies according to iron and zinc
availability (13, 21, 22). It is possible that expression of the com-
plementing genes from a heterologous, constitutive promoter al-
tered the stoichiometry of Esx-3 components, which in turn re-
sulted in suboptimal protein secretion.
We attempted to measure secreted proteins using native anti-
bodies and Western blotting. However, the antisera that we were
able to obtain had low affinity and poor specificity, making quan-
titation difficult. Given the tendency of secretion systems to be
refractory to reporter fusions (52), we turned to MRM-MS to
measure bacterial protein export. This label-free method is highly
specific and sensitive and is likely to have broad applicability to
bacterial protein secretion studies (53).
Precise quantitation of secretion by MRM-MS revealed a sur-
prising dynamic range in the levels of EsxG and EsxH export that
support iron acquisition. We were able to restore esx-3 mutant
growth to wild-type levels by adding iron to the growth medium
(Fig. S2) or by complementing the deleted genes (Fig. 2). How-
ever, the same genetic constructs varied widely in their abilities to
restore EsxGms and EsxHms export (Fig. 4 and 5). Only a fraction of
secreted wild-type EsxGms and EsxHms levels appeared necessary
for complementation; we observed robust low-iron growth
(Fig. 2) concomitant with protein export that spanned 3 orders of
magnitude, from1% to approximately 40% of wild-type levels
(Fig. 4). We recently found that the essential drug targets dihydro-
folate reductase and D-alanine racemase are present in excess (54).
It is possible that wild-type M. smegmatis exports EsxGms and
EsxHms at levels much greater than those needed to support low-
iron growth. This raises the possibility that the locus has multiple
functions, each with different secretion requirements.
Indeed, there is growing appreciation that the relationship be-
tween Esx protein export and function is more complex than ini-
tially assumed. There are now numerous reports of Esx-1 muta-
tions that attenuate pathogenic mycobacteria without impacting
secretion. For example, complementation of the natural esx-1mu-
tant M. microti (Fig. 1) with a panel of cosmids containing intact
or mutant versions of theM. tuberculosis esx-1 region revealed that
espF1mt and espG1mt are required for virulence but not EsxBmt and
EsxAmt export (35). Deletion of these genes from M. tuberculosis
also resulted in attenuation without impacting the secretion of
EsxBmt and EsxAmt (42). In a different example, disruption of
disulfide bond formation in the Esx-1 substrate EspA attenuated
M. tuberculosis virulence but had no effect on EsxBmt or EsxAmt
secretion (43). Finally, transposon insertions in espJms, espKms,
and espBms impaired conjugation but not EsxBms export (4). In
aggregate, these studies show that secretion of EsxB and EsxA is
not sufficient for Esx-1 function in virulence.
Recently, Chen and coworkers isolated two point mutations of
EspAmt that block EsxBmt and EsxAmt export in vitro but do not
attenuate M. tuberculosis (44). Although they did not rule out a
role for the host environment in permitting secretion in vivo, these
data suggest that export of these proteins, at least in large amounts,
may not be strictly required for virulence. Similarly, we found a
mutation that inhibits Esx protein secretion but permits partial
function: loss of mycP3ms blocked the export of native EsxGms and
EsxHms and FLAG-tagged EsxHms (Fig. 4 and 5), yet the fxbA
mycP3ms mutant retained some ability to grow in low iron
(Fig. 2). We also found that very low quantities of EsxGms and
EsxHms secretion were sufficient to reinstate low-iron growth to
some of our complemented esx-3 mutants (Fig. 2 and 4). Impor-
tantly, dissection of the Esx-3 system in the model organism
M. smegmatis allowed us to compare the two phenotypes, EsxG
and EsxH export and mycobactin-mediated iron acquisition, un-
der similar in vitro conditions.
Why are not protein secretion and iron utilization completely
congruent in our mutant strains? This is especially puzzling given
that the genome of M. smegmatis, unlike M. tuberculosis, does not
encode the closely related paralogs EsxR and EsxS, which might
otherwise be hypothesized to substitute for EsxG and EsxH func-
tion (8). One reason may be the existence of multiple Esx sub-
strates, each with its own requirements for export and contribu-
tions to function. The roles of EspG and EspB are particularly
informative in this regard. Inactivation of the paralogous espG1,
espG5, or, as we show in Fig. 4, espG3 gene generally prevents the
export of Esx substrate proteins (11, 17, 37, 42). However, in
M. tuberculosis, loss of EspG5mt did not produce an obvious phe-
notype (55), while EspG1mt was required for full virulence but not
EsxBmt or EsxAmt secretion (35, 42). Interestingly, EspG1 and
EspG5 have been shown to interact specifically with cognate Pro-
Glu (PE)/Pro-Pro-Glu (PPE) proteins (56, 57) and have been pro-
posed to serve as chaperones for Esx secretion of these substrates
(57). These data suggest that the PE/PPE proteins have export
requirements and functional contributions distinct from those of
other type VII substrates. Similarly, the secretion and activity of
the Esx-1 substrate EspB appear to be independent of EsxA (58,
59) and EsxB (60).
Our data are consistent with at least three general models. It is
conceivable that loss of Esx-3 function produces global changes in
cell wall structure such that protein localization is affected by
changes both in secretion and in the compartment into which
translocation occurs. We note that while esx-3 mutants do not
have altered sensitivities to SDS, vancomycin, rifampin (Fig. S5),
ampicillin, or kanamycin (19), at least when iron is not limiting,
we are unable to rule out this model. A second possibility is that
Esx-3 secretes a protein or proteins necessary for iron acquisition
and that this protein requires the core components EccC3, EccD3,
and EspG3 but not EsxG, EsxH, or MycP3 for export. Although it
is possible that Esx-3 function in iron acquisition does not require
any EsxG and EsxH secretion, we think that this is unlikely given
that the fxbAesxGHms strain has a complementable growth phe-
notype in low iron. A third model is that both EsxG and EsxH are
substrates and structural components of or chaperones for the
Esx-3 machinery. In this scenario, EsxG and EsxH are exported
across the cytoplasmic membrane via EccD3 into the periplasm,
where they are poised to deliver yet-unidentified effectors of ferri-
mycobactin uptake across the remainder of the cell wall (Fig. 6). If
EsxG and EsxH indeed act within or across the mycobacterial
envelope, some of the protein detected in the supernatants of
broth-grown mycobacteria may represent sloughing of protein
associated with the cell wall (33, 34).
While type VII secretion systems have important functions
Siegrist et al.
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both in vitro and in vivo, their molecular mechanisms remain un-
clear. Clearly, protein export contributes to but does not entirely
account for type VII function. More complete models for type VII
structure-function relationships will require better characteriza-
tion of secreted components and assays for protein-protein inter-
actions that occur between Esx components in the cytosol or
membrane (55, 61).
MATERIALS AND METHODS
Bacterial strains and growth conditions. M. smegmatis was cultured in
chelated Sauton’s medium containing 60 ml glycerol, 0.5 g KH2PO4, 2.2 g
citric acid monohydrate, 4 g asparagine, and 0.05% Tween 80 per liter.
After adjusting the pH to 7.4, the medium was stirred for 1 to 2 days at
room temperature with 10 g Chelex 100 resin (Sigma). The medium was
filtered, and 1 g MgSO4·7H2O was added as a sterile solution. For iron
starvation experiments, bacteria were first inoculated from frozen stocks
into 7H9 medium, subcultured once in chelated Sauton’s medium, and
then diluted 1:1,000 in chelated Sauton’s medium without antibiotics
containing either 100M 2,2=-dipyridyl or 12.5M FeCl3. For mycobac-
tin complementation experiments, bacteria were directly diluted 1:1,000
from a 7H9 starter culture into chelated Sauton’s medium with or without
ferri-mycobactin S.
Strain construction. To create the M. smegmatis esx-3 gene deletions,
1-kb regions flanking eccC3ms, espG3ms, eccD3ms, mycP3ms, and esxGHms
were amplified from M. smegmatis genomic DNA, stitched together by
PCR, and cloned into the suicide vector pJM1. The pJM1 vector contains
a hygromycin-chloramphenicol resistance cassette and the counterselect-
able marker sacB. M. smegmatis transformants were screened by PCR
using primers specific to the flanks as well as to regions within the putative
deletion. Candidates were confirmed by PCR using multiple primers out-
side the flanks. To construct fxbA insertional mutants, the esx-3 deletion
strains were transformed with the pSES-fxbA suicide vector (13) and
screened by standard methods. The absence of exochelin production was
confirmed for candidate mutants by patching them to chrome azurol
(CAS) agar.
Complementing constructs for each mutant were constructed by am-
FIG 6 One model for Esx-3 function in which EsxG and EsxH are both substrates and chaperones or structural components of the secretion apparatus. IrtA and
IrtB are components of a mycobactin transporter system (63– 65). We hypothesize that at least one of the functions of EsxG and EsxH is to ferry effectors of
iron-loaded mycobactin uptake within or across the mycobacterial cell wall. In the absence of an Esx-3 core component, such as EccD3, we do not detect EsxG
or EsxH in culture supernatants. We hypothesize that the proteins are not exported across the cytoplasmic membrane under this condition and therefore are
completely unable to contribute to iron acquisition. In contrast, although supernatants from fxbA mycP3ms cultures do not contain detectable EsxG or EsxH,
the strain itself retains intermediate growth under low-iron conditions. We suggest the MycP3 protease may be an accessory Esx-3 component that is required
either for a stable EsxG-EsxH structure or for optimal chaperone activity. Thus, in the absence of this accessory factor, EsxG and EsxH may still traverse the
cytoplasmic membrane to the periplasm but be only partially functional.
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plifying the regions from genomic M. smegmatis DNA and cloning them
under the MOP promoter in the integrative pJEB402 plasmid (38). The
construct containing esxGms and esxHms C-terminally tagged with FLAG
was generated by amplifying the region from genomicM. smegmatisDNA
and cloning it under the control of the hsp60 promoter of pSYMP (62).
SID, MRM-MS. (i) Labeled-peptide internal standards. Figure S3
shows the amino acid sequences of the proteins EsxGms and EsxHms and
the peptides that were selected for quantitative analysis of these proteins
by multiple-reaction-monitoring mass spectrometry (MRM-MS). A pep-
tide from each of the proteins was selected based on their detection in the
discovery data by high electrospray MS signal responses and because they
have unique sequences as determined by a search of the nonredundant
M. tuberculosis protein database (NCBI nr). Four different versions of the
peptide AMATTHEQNTMAMSAR for the EsxHms protein were selected,
all of which were observed in the discovery data.
(ii) Peptide synthesis. Five signature peptides from the two proteins,
EsxGms (FVEVSAK) and EsxHms (AMATTHEQNTMAMSAR, with four
forms of differing oxidized methionine states), were synthesized with a
single, uniformly labeled [13C6]lysine or [13C6]arginine at their C termini
by New England Peptide (Gardner, MA). Unlabeled 12C-labeled forms of
each peptide were also synthesized by New England Peptide. Synthetic
peptides were purified to99% purity and analyzed by amino acid anal-
ysis (New England Peptide). Calculations of concentrations were based
upon amino acid analysis.
(iii)MRM-MS assay configuration.The limits of detection and quan-
tification (LOD and LOQ, respectively) for the signature peptides used to
obtain quantitative measurements in each of the 22 samples (5 mutants, 5
complemented mutants and 1 wild-type strain in each of two biological
process replicates) are shown in Fig. S4. A 12-point response curve was
generated by spiking light peptide versions of the 5 analyte peptides over a
range of 0 to 50 fmol/1 g of digested supernatant protein and a fixed
amount of heavy, internal-standard peptides (1 fmol/1 g) of the super-
natant protein mix from the esxGHms sample. This supernatant of the
esxGHms sample was used as the background matrix for response curve
generation, as it does not express the proteins of interest. Each concentra-
tion point was analyzed by liquid chromatography (LC)–MRM-MS on a
Waters Xevo TQ mass spectrometer (Milford, MA) in three technical
replicates. The LOD was determined by the Linnet statistical method, and
the lower LOQ was calculated as 3 times the LOD. The blank sample
consists of theesxGHms sample with only the isotopically labeled (heavy)
peptides spiked in.
(iv) Nano-LC–MRM-MS. Tryptic peptides were prepared from cul-
ture supernatants (see below) and reconstituted in 80 l of 0.1% formic
acid, and 1 g/liter of each sample was used for MRM-MS analysis.
Nano-LC–MRM-MS was performed on a Xevo TQ mass spectrometer
(Waters Corporation, Milford, MA) coupled to a Nano Acuity LC system.
Chromatography was performed with solvent A (0.1% formic acid) and
solvent B (100% acetonitrile in 0.1% formic acid). Each sample was in-
jected with a full-loop injection of 1 l on a Waters, packed, Reprosil,
3-m-bead column (75-m internal diameter [ID], 10-m ID tip open-
ing) with a 2.5-in by 20-m ID spray needle. Sample was eluted at 300 nl/
min, with a gradient of 3 to 7% solvent B for 8 min, 7 to 40% solvent B for
34 min, and 40 to 90% solvent B for 3 min, with a total data acquisition
time of 80 min. Data were acquired with a stable column temperature of
35°C. Collision energy (CE) was optimized for the maximum transmis-
sion and sensitivity of each MRM transition by LC–MRM-MS. Three
transitions were monitored per peptide and acquired at unit resolution
both in the first and in the third quadrupole (Q1 and Q3). In general,
transitions were chosen based upon relative abundance and a mass-to-
charge ratio (m/z) greater than the precursor m/z in the full-scan tandem
MS (MS/MS) spectrum recorded on the Xevo TQ mass spectrometer. The
final MRM-MS method consisted of 10 optimized transitions for each of
the five selected peptides from the two target proteins. One of the four
peptides (AMATTHEQNTMAMSAR) was not used for data analysis due
to a weak signal.
(v) MRM-MS data analysis. Data analysis was performed using the
Skyline Software Module (https://skyline.gs.washington.edu/). The rela-
tive ratios of the three transitions selected and optimized for the final
MRM assay were predefined in the absence of the target proteins (i.e., in
buffer) for each peptide using the 13C-labeled internal standards. The
most abundant transition for each pair was used for quantification unless
interference in this channel was observed. The 12C/13C peak area ratios
were used to calculate concentrations of the target peptides in each sample
by the following equation: measured concentration  peak area ratio 
(1 fmol/l internal standard).
Sample preparation for MRM-MS analysis. Strains were inoculated
from frozen stocks in 7H9 medium with appropriate antibiotics and
grown with shaking for 48 h. The cells were then washed twice in chelated
Sauton’s medium, normalized by their optical densities at 600 nm
(OD600s), and inoculated 1:500 into chelated Sauton’s medium. Cultures
were grown for 48 h to log phase, and 8 OD units were harvested. Bacteria
in the pellets were lysed by bead beating, and the lysates were stored at
80°C. Protein from the supernatant was precipitated by the trichloro-
acetic acid (TCA) method and dissolved in urea-ammonium-bicarbonate
buffer (8 M urea, 50 mM ammonium bicarbonate). Protein concentration
was measured by the Bradford assay of diluted samples.
One hundred micrograms of protein was reduced by 20 mM dithio-
threitol (DTT) and alkylated using 50 mM iodoacetamide. Prior to being
digested with trypsin, samples were diluted to a urea concentration of
0.6 M by the addition of 50 mM ammonium bicarbonate. Trypsin (Pro-
mega Gold) digestion was carried out at an enzyme-to-substrate ratio of
1:50. The peptides were desalted using Sep-Pak cartridges (Sep-Pak C18
1-cc [50-mg] Vac cartridges; Waters) as described by the manufacturer. In
the final step, samples were eluted in 80% acetonitrile and 0.1% formic
acid and evaporated to complete dryness in a vacuum centrifuge.
Immunoblotting. Strains were inoculated from frozen stocks into
7H9 medium and grown to saturation. They were then diluted 1:500 in
chelated Sauton’s medium, grown to saturation, and diluted 1:100 in che-
lated Sauton’s medium. Proteins from cell pellets and supernatants of
cultures grown for 12 h in this fashion were run on 10 to 20% Tris-Tricine
gels (Invitrogen) and revealed using an anti-FLAG antibody. An antibody
to RNA polymerase (RNAP; Neoclone W0023), an intracellular protein,
served as a loading and lysis control.
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